Intranasal Administration of TAT-haFGF14–154 Attenuates Disease Progression in a Mouse Model of Alzheimer’s Disease
G. Lou,Q. Zhang,F. Xiao,Q. Xiang,Z. Su,L. Zhang,P. Yang,Y. Yang,Q. Zheng,Y. Huang
DOI: https://doi.org/10.1016/j.neuroscience.2012.08.003
IF: 3.708
2012-01-01
Neuroscience
Abstract:Human acidic fibroblast growth factor (haFGF), a neurotrophin-like growth factor in the brain, plays important roles in the development, differentiation and regeneration of brain neurons, which makes it potential to treat Alzheimer's disease (AD). In this study, haFGF(14-154) and TAT-haFGF(14-154) (haFGF(14-154) fused with the cell-penetrating peptide transactivator of transcription protein transduction domain (TAT-PTD)) were intranasally administrated for 5 weeks to investigate the effects on senescence-accelerated mouse prone-8 (SAMP8) mice (a mouse model of AD). Results showed that TAT-PTD could increase the concentration of haFGF in the brain significantly, and TAT-haFGF(14-154) was more effective than haFGF(14-154) in the same dosage (300 mu g/kg). Importantly, TAT-haFGF(14-154) improved the learning and memory abilities of SAMP8 mice in the behavioral test, and promoted the function of cholinergic system by measuring the relevant biomarkers (acetylcholine (ACh) level, acetylcholinesterase (AChE) and choline acetyltransferase (ChAT) activities). TAT-haFGF(14-154) also significantly reduced beta-amyloid protein(1-42) (A beta(1-42)) deposits as well as the levels of A beta soluble forms in the mice brains and prevented the neurons from apoptosis. Besides, the oxidative stress impairment in the brain and serum was also ameliorated. The results suggest that TAT-haFGF(14-154) could attenuate the disease progression of SAMP8 AD mice, and the mechanism is related to the regulation of neurons micro-environment including neurotransmitters, A beta pathology and oxidative stress. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.